Loading...
Docoh

Pear Therapeutics (PEAR)

News

From Benzinga Pro
Where Pear Therapeutics Stands With Analysts
24 Jun 22
Analyst Ratings
Within the last quarter, Pear Therapeutics (NASDAQ:PEAR) has observed the following analyst ratings:
BTIG Maintains Buy on Pear Therapeutics, Lowers Price Target to $11
24 Jun 22
News, Price Target, Analyst Ratings
BTIG analyst Marie Thibault maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $12 to $11.
Pear Therapeutics Earnings Perspective: Return On Capital Employed
21 Jun 22
Earnings
According to data from Benzinga Pro, during Q1, Pear Therapeutics's (NASDAQ:PEAR) reported sales totaled $2.75 million. Despite a 62.5% increase in earnings, the company posted a loss of $23.86 million.
Stocks That Hit 52-Week Lows On Tuesday
14 Jun 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Tuesday, 951 companies hit new 52-week lows.
Pear Therapeutics Highlights New 12-Month Analysis Showing Reduction In Healthcare Resource Utilization And Associated Costs In Patients Treated With reSET-O
14 Jun 22
Biotech, General
reSET-O® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of opioid use disorder (OUD) Results support the real-world value of reSET-O, demonstrating durable treatment outcomes
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
14 Jun 22
Pre-Market Outlook, Markets, Movers
93 Biggest Movers From Yesterday
14 Jun 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
Stocks That Hit 52-Week Lows On Monday
13 Jun 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Monday's trading, 1214 companies set new 52-week lows.
70 Stocks Moving In Monday's Mid-Day Session
13 Jun 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
91 Biggest Movers From Friday
13 Jun 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Stocks That Hit 52-Week Lows On Friday
10 Jun 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 422 stocks made new 52-week lows.
95 Biggest Movers From Yesterday
7 Jun 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 100.4% to close at $4.75 on Monday after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.
Mid-Afternoon Market Update: Dow Turns Lower; DiDi Global Shares Surge
6 Jun 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
U.S. stocks pared gains, with the Dow Jones turning lower toward the end of trading on Monday.
12 Health Care Stocks Moving In Monday's Intraday Session
6 Jun 22
Intraday Update, Markets, Movers
Mid-Day Market Update: Nasdaq Rises 1%; Praxis Precision Medicines Shares Plunge
6 Jun 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Monday.
52 Stocks Moving In Monday's Mid-Day Session
6 Jun 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers DiDi Global Inc. (NYSE: DIDI) jumped 51.4% to $2.80 after the Chinese government said the company can resume adding new users.
Pear Therapeutics Announces New Analysis Showing Reduction In Healthcare Resource Utilization And Associated Costs In Patients Using reSET At 6 Months
6 Jun 22
News, FDA
Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months reSET® is the only FDA-authorized prescription
69 Biggest Movers From Friday
6 Jun 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Chardan Capital Maintains Buy Rating for Pear Therapeutics: Here's What You Need To Know
17 May 22
Analyst Ratings
Chardan Capital has decided to maintain its Buy rating of Pear Therapeutics (NASDAQ:PEAR) and lower its price target from $16.00 to $13.00. Shares of Pear Therapeutics are trading up 9.75% over the last 24 hours, at $3.94 per share.
10 Biggest Price Target Changes For Tuesday
17 May 22
Penny Stocks, Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday.

Press releases

From Benzinga Pro
Pear Therapeutics to Participate in the Cowen 7th Annual FutureHealth Conference
16 Jun 22
Press Releases
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Cowen's 7th
Pear Presents Interim Real-World Data Showing Significant Reductions in Symptoms of Chronic Insomnia, Anxiety and Depression with Somryst® at SLEEP 2022
8 Jun 22
Press Releases
Interim results from the DREAM trial showed treatment with Somryst, a prescription digital therapeutic (PDT) for patients with chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and
Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months
6 Jun 22
Press Releases
reSET® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of substance use disorder (SUD), including alcohol, cannabis, cocaine, and stimulants Results support the real-world
Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022
19 May 22
Press Releases
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual
Pear Therapeutics Reports First Quarter 2022 Financial Results
16 May 22
Press Releases
108% quarter-over-quarter revenue growth to $2.7 million >9,200 total prescriptions in the first quarter for Pear's three FDA-authorized products Expanded patient access with state payors in Michigan and
Pear Therapeutics to Participate in the Bank of America 2022 Healthcare Conference
3 May 22
Press Releases
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Bank of
Pear Therapeutics to Issue First Quarter 2022 Financial Results on Monday, May 16, 2022
2 May 22
Press Releases
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the company will issue its first quarter
Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit
18 Apr 22
Press Releases
Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the treatment of substance use and opioid use disorders Pear Therapeutics, Inc.
Pear Therapeutics Receives Safer Technologies Program (STeP) Designation from FDA for Product Candidate to Treat Acute and Chronic Pain
13 Apr 22
Press Releases
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it has received Safer Technologies Program
Jorge Gomez Joins Moderna as Chief Financial Officer
11 Apr 22
Management, Press Releases
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief
Pear Therapeutics Announces Program to Bring Prescription Digital Therapeutics to Patients in Recovery Through a Telehealth Provider Experience
4 Apr 22
Press Releases
Pear is working with select telehealth providers to put recovery in the hands of those seeking help remotely Pear's first telehealth offering is with PursueCare, a leading telehealth addiction treatment provider, to
Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
28 Mar 22
Press Releases
$4.2 million total revenue for the full year 2021 2021 highlights include Current Procedural Terminology (CPT) codes for prescribers, first state Medicaid coverage decision, two major PBM formulary additions, more